Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYAI NASDAQ:GBIO NASDAQ:MAAQ NASDAQ:MBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$0.75-6.5%$0.97$0.71▼$2.20$28.95M0.89246,708 shs179,577 shsGBIOGeneration Bio$6.29-5.6%$4.12$3.00▼$29.40$44.86M2.67854,522 shs188,256 shsMAAQMana Capital Acquisition$3.74+7.5%$4.01$5.35▼$10.25$30.39MN/A33,075 shs56,344 shsMBIOMustang Bio$1.77-0.6%$1.69$0.89▼$21.95$7.79M2.22240,022 shs99,303 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International-2.44%-15.78%-18.38%-23.08%-40.30%GBIOGeneration Bio+0.76%+60.48%+56.34%+74.67%-71.42%MAAQMana Capital Acquisition0.00%-5.08%-9.88%-6.50%+790.48%MBIOMustang Bio-4.81%+17.11%-25.52%+58.93%-89.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDYAIDyadic International3.3865 of 5 stars3.55.00.00.02.43.30.0GBIOGeneration Bio3.2982 of 5 stars3.33.00.00.02.13.31.3MAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio1.2293 of 5 stars0.05.00.00.03.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYAIDyadic International 3.00Buy$6.00701.82% UpsideGBIOGeneration Bio 2.67Moderate Buy$37.33493.53% UpsideMAAQMana Capital Acquisition 0.00N/AN/AN/AMBIOMustang Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MBIO, DYAI, MAAQ, and GBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025GBIOGeneration BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$7.00 ➝ $7.008/13/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.007/18/2025GBIOGeneration BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.00 ➝ $70.00(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYAIDyadic International$3.49M7.76N/AN/A($0.01) per share-74.83GBIOGeneration Bio$19.89M2.13N/AN/A$8.03 per share0.78MAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/A$0.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYAIDyadic International-$5.81M-$0.190.00N/AN/A-134.84%-355.39%-60.66%N/AGBIOGeneration Bio-$131.67M-$10.820.00N/AN/A-341.12%-91.07%-33.65%N/AMAAQMana Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AMBIOMustang Bio-$15.75M-$78.000.00N/AN/AN/AN/A-29.49%N/ALatest MBIO, DYAI, MAAQ, and GBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025DYAIDyadic International-$0.06-$0.06N/A-$0.06$0.60 million$0.97 million8/12/2025Q2 2025GBIOGeneration Bio-$2.80-$3.12-$0.32-$3.12$2.51 million$0.77 million8/8/2025Q2 2025MBIOMustang BioN/A-$0.19N/A-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYAIDyadic InternationalN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYAIDyadic International5.402.023.98GBIOGeneration BioN/A7.518.43MAAQMana Capital AcquisitionN/AN/AN/AMBIOMustang BioN/A1.301.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYAIDyadic International27.95%GBIOGeneration Bio95.22%MAAQMana Capital Acquisition68.44%MBIOMustang Bio9.95%Insider OwnershipCompanyInsider OwnershipDYAIDyadic International29.50%GBIOGeneration Bio21.80%MAAQMana Capital AcquisitionN/AMBIOMustang Bio0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYAIDyadic International736.19 million21.21 millionOptionableGBIOGeneration Bio1506.74 million5.27 millionOptionableMAAQMana Capital Acquisition18.13 millionN/ANot OptionableMBIOMustang Bio1004.38 million4.37 millionNot OptionableMBIO, DYAI, MAAQ, and GBIO HeadlinesRecent News About These CompaniesMustang Bio Inc.July 25, 2025 | barrons.comTalisker Receives Assay Results from 1105 Level Lateral Development at the Mustang MineJuly 24, 2025 | globenewswire.comMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - NasdaqJuly 10, 2025 | nasdaq.comMustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer DrugJuly 10, 2025 | msn.comBiotech Stock Mustang Bio, Inc. (Nasdaq: MBIO) Soars on Orphan Drug Designation by U.S. FDAJuly 9, 2025 | investorideas.comIMustang Bio Inc News (MBIO) - Investing.comJuly 9, 2025 | investing.comMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer TherapyJuly 8, 2025 | zacks.comDow Dips 1%; Mustang Bio Shares Spike HigherJuly 7, 2025 | benzinga.comThis BlackRock stock just spiked over 300%July 7, 2025 | finbold.comFMustang Bio stock soars after FDA grants orphan drug designationJuly 7, 2025 | investing.comMustang Bio rises after FDA orphan drug status for MB-101July 7, 2025 | msn.comMustang Bio Shares Surge After FDA Grants Orphan Drug StatusJuly 7, 2025 | msn.comMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and GlioblastomaJuly 7, 2025 | globenewswire.comMustang Bio, Inc. (MBIO) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comMustang Bio treatment of malignant glioma granted orphan designationJuly 2, 2025 | msn.comMBIO Mustang Bio, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comMustang Bio’s first-of-a-kind CAR-T starts trialsMay 1, 2025 | pharmaphorum.comPMustang Bio meets Nasdaq’s equity listing requirementsMarch 7, 2025 | investing.comMustang Bio Regains Nasdaq Compliance, Secures Position For Cell Therapy AdvancementsMarch 7, 2025 | nasdaq.comMustang Bio regains compliance with Nasdaq requirementMarch 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBIO, DYAI, MAAQ, and GBIO Company DescriptionsDyadic International NASDAQ:DYAI$0.75 -0.05 (-6.46%) Closing price 03:59 PM EasternExtended Trading$0.79 +0.04 (+5.57%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Generation Bio NASDAQ:GBIO$6.29 -0.37 (-5.56%) Closing price 04:00 PM EasternExtended Trading$6.58 +0.29 (+4.53%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Mana Capital Acquisition NASDAQ:MAAQ$3.74 +0.26 (+7.47%) As of 08/12/2025Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.Mustang Bio NASDAQ:MBIO$1.77 -0.01 (-0.56%) Closing price 04:00 PM EasternExtended Trading$1.74 -0.03 (-1.64%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Arista Networks: Cashing In as the Tollbooth for AI Traffic Green Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access